Form 4: Viracta Therapeutics Director Thomas E. Darcy Acquires Stock Options

Director Thomas E. Darcy acquired stock options in Viracta Therapeutics, Inc. on June 20, 2024.

Summary

• On June 20, 2024, Thomas E. Darcy, a director of Viracta Therapeutics, Inc., acquired stock options to purchase 50,000 shares of common stock at an exercise price of $0.569 per share.
• The options vest monthly starting from the grant date, or fully upon the next annual stockholder meeting, contingent on continued service.
• A Power of Attorney was executed, granting Michael E. Faerm, Mark Rothera, Stewart Brown, Sanja Lazic, Ben Capps, and Brandon Shaw the authority to act on Darcy's behalf for SEC filings.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants. The director's acquisition could be interpreted as a slightly positive signal, but it's not a major event.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Viracta Therapeutics, Stock Options, Director, Form 4, SEC, Thomas E. Darcy, Beneficial Ownership, Equity, Power of Attorney